Balaxi Pharmaceuticals Limited (BALAXI.NS) Stock Overview
Explore Balaxi Pharmaceuticals Limited’s financial performance, market position, analyst ratings, and future outlook.
Balaxi Pharmaceuticals Limited (BALAXI.NS)
Key Financials
Key Financials
Market Cap
1.2B
P/E Ratio
49.78
EPS (TTM)
$-5.30
ROE
0.01%
BALAXI.NS Stock Analysis & Investment Overview (NSE)
Our AI-powered analysis of Balaxi Pharmaceuticals Limited (NSE: BALAXI.NS) gives investors deep insight into how the stock performs on the NSE exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Balaxi Pharmaceuticals Limited's NSE-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of BALAXI.NS on the NSE shows an RSI of 31.94, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $0.00 for the NSE listing.
Key metrics behind Balaxi Pharmaceuticals Limited's NSE-traded stock include a P/E ratio of 49.78 and a market capitalization of 1.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of BALAXI.NS on the NSE.